Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173130 | 0.86 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL96483 | 0.79 | KDM4E (0.35) | — | |
| SCHEMBL173133 | 0.78 | CHRM2 (0.31) | — | |
| SCHEMBL173137 | 0.78 | SIGMAR1 (0.31) | — | |
| SCHEMBL96481 | 0.78 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL19663806 | 0.78 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14095920 | 0.78 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL96772 | 0.76 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL13394409 | 0.76 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16316905 | 0.75 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059008-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080548-B2 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100099678-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA (US) | 2010-04-22 | — | — | US | disclosed |
| US-7632836-B2 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090111813-A1 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059008-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PMP22, CNR2, COQ8A | CHRNB2 1308/4885CHRNB4 2248/4885CHRNA3 1067/4885 |
| US-20100099678-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PMP22, CNR2, COQ8A | CHRNB2 1308/4885CHRNB4 2248/4885CHRNA3 1067/4885 |
| US-20090111813-A1 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | PMP22, CNR2, COQ8A | CHRNB2 1308/4885CHRNB4 2248/4885CHRNA3 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.